Clinical outcomes of the AdaptResponse trial - Authors' reply

Affiliations

¹ National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens 124 61, Greece. Electronic address: gfilippatos@gmail.com.
² Medical University of South Carolina, Charleston, SC, USA.
³ Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; Hasselt University, Hasselt, Belgium.
⁴ National Cerebral and Cardiovascular Center, Osaka, Japan.
⁵ King Saud University, Faculty of Medicine, Riyadh, Saudi Arabia.
⁶ University of Ottawa Heart Institute, Ottawa, ON, Canada.
⁷ Medtronic Bakken Research Center, Maastricht, Netherlands.
⁸ University of Rennes, Rennes, France.

Gerasimos Filippatos et al. Lancet. 2024.

. 2024 Jun 8;403(10443):2484-2485.

doi: 10.1016/S0140-6736(24)00866-3.

¹ National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens 124 61, Greece. Electronic address: gfilippatos@gmail.com.
² Medical University of South Carolina, Charleston, SC, USA.
³ Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; Hasselt University, Hasselt, Belgium.
⁴ National Cerebral and Cardiovascular Center, Osaka, Japan.
⁵ King Saud University, Faculty of Medicine, Riyadh, Saudi Arabia.
⁶ University of Ottawa Heart Institute, Ottawa, ON, Canada.
⁷ Medtronic Bakken Research Center, Maastricht, Netherlands.
⁸ University of Rennes, Rennes, France.

No abstract available

Comment in

Clinical outcomes of the AdaptResponse trial.
Komamura K, Iwase M. Komamura K, et al. Lancet. 2024 Jun 8;403(10443):2484. doi: 10.1016/S0140-6736(24)00867-5. Lancet. 2024. PMID: 38851282 No abstract available.